GlobalData has
released its new Country report, PharmaPoint: Meningococcal Vaccines United
Kingdom Drug Forecast and Market Analysis to 2022. Meningococcal disease is an
acute infection caused by the gram-negative bacterium Neisseria meningitidis.
Its rapid onset and severity of symptoms makes prompt and effective diagnosis
and treatment nearly impossible. For these reasons the meningococcal disease
space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such
as Sanofis Menactra and Novartis Menveo, account for the vast majority of
global sales, with the US adolescent market being the key target segment.
GlobalData expects growth in the meningococcal vaccines market to be primarily
driven by the launch of serotype B vaccines, which address a critical unmet
need in the treatment landscape. Vaccines that better protect infants and/or
provide a longer duration of immunity also have an opportunity to seize market share
during 2012-2022.
To
Read The Complete Report with TOC :-
GlobalData
predicts that relative patient share for the three MenC conjugate vaccines will
shift due to changes being made to the UK MenC schedule (DOH, 2013b).
Meningitec will lose sales due to its elimination from the single primary dose,
with patient share expected to be made up by Menjugate and NeisVac-C.
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market.
To Buy a Copy Of This Report:-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment